FOLH1 and prostate carcinoma: Prostate‐specific membrane antigen (PSMA) is a type II, transmembrane glycoprotein that is highly expressed on prostate cancer epithelial cells as well as the endothelium of tumour‐associated neovasculature in non‐prostate cancers.9